Senate Passes Bill to Prevent Contaminated Infant Formula Sales
The U.S. Senate has unanimously approved a bill introduced by Democratic Michigan Senator Gary Peters aimed at preventing the sale of contaminated infant formula. This decision comes after formula produced by Abbott’s plant in Sturgis, Michigan, was linked to the deaths of two infants and severe illness in others in 2021 and 2022.
Senator Peters emphasized the chaos caused by the subsequent recall, especially after shortages experienced during the COVID-19 lockdowns. Families across the nation faced challenges as individuals began hoarding infant formula out of fear of shortages, creating a sense of panic among caregivers.
The bill mandates that formula plants conduct contaminant testing before shipping to stores and promptly notify the Food and Drug Administration (FDA) in case of any contamination findings. Senator Peters expressed concerns about the FDA’s ability to respond promptly to such issues due to recent staffing reductions within the agency.
In addition to the new bill, the FDA is required to deliver a report to Congress on its progress in implementing recommendations made in 2025 to address vulnerabilities highlighted during the 2022 formula shortage. Recently, the FDA indicated that around 48 infants may have fallen ill due to botulism in infant formula produced by a New York-based company.
Senator Peters is now focused on garnering support from House members to pass a similar bill, ensuring the safety and well-being of infants nationwide.
